Evidence map›Paper›PMID 41531962›Full record

ArticleACS medicinal chemistry letters2026

Quinazolinones as Bioisosteres of Naphthoquinones: A Path to Potent

Bruna F Godoi, Jéssica D Bueno, Wemenes J L Silva, Aline D da Purificação, Pedro I P Leite, Thiago Dos Santos, Murillo Freitas, Daniel G Silva, Tais C Silva, Josué de Moraes and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Bruna F GodoiCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Jéssica D BuenoCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Wemenes J L SilvaCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Aline D da PurificaçãoCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Pedro I P LeiteCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Thiago Dos SantosCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Murillo FreitasCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.
Daniel G SilvaCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.ORCID https://orcid.org/0000-0001-8879-456X
Tais C SilvaResearch Center on Neglected Diseases, Guarulhos University, Guarulhos 07023-070, SP, Brazl.
Josué de MoraesResearch Center on Neglected Diseases, Guarulhos University, Guarulhos 07023-070, SP, Brazl.
Caroline S FreitasLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.
Mayara MattosLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.
Thiago M L SouzaLaboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro 21040-360, RJ, Brazil.
Bianca A MartinInnovation Center in Nanostructured Systems and Topical Administration (NanoTop), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 05508-060, SP, Brazil.
Renata F V LopezInnovation Center in Nanostructured Systems and Topical Administration (NanoTop), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 05508-060, SP, Brazil.
M Cristina NonatoCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.ORCID https://orcid.org/0000-0002-4916-1505
Carolina H AndradeCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.ORCID https://orcid.org/0000-0003-0101-1492
Flavio S EmeryCenter for the Research and Advancement in Fragments and Molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, Brazil.

Funding

Validation of Trypanosoma cruzi dihydroorotate dehydrogenase as a drug target for Chagas´disease.R01AI160379 · NIAID · UNIVERSITY OF SAO PAULO · PI EMERY, FLAVIO DA SILVA, NONATO, MARIA CRISTINA · 2021 to 2025
$659k
NIAID NIH HHS R01 AI160379
6 · The paper itself

Abstract

Human dihydroorotate dehydrogenase (

Indexed as

host-directed therapyhuman dihydroorotate dehydrogenasequinazol­inonesSARS-CoV-2SBDD

Identifiers

PMID41531962
PMCPMC12794095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.